Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
By Sriparna Roy April 13 (Reuters) - Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live ...
New England's 12 goals in its first six matches is the second-highest rate in team history, and they're come from nine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results